Racial Disparities and Trends in Alzheimers and Parkinsons Disease-Related Mortality: A CDC WONDER Study 2018-2024
- 1University ofSouth Florida
Abstract
ObjectiveThe objectives of this study were to examine racial differences and temporal trends in Alzheimers disease (AD)- and Parkinsons disease (PD)-related mortality among U.S. adults and to assess whether racial mortality patterns and temporal changes differed.
MethodsWe analyzed CDC WONDER Multiple Cause of Death data from 2018-2024, where mortality was defined as deaths with AD or PD recorded as an underlying or contributing cause. Age-standardized mortality rates and adjusted mortality rate ratios (MRRs) were estimated. Joint-point regression evaluated racial differences, annual percentage changes (APCs), and disease-race-year interactions. Sensitivity analyses assessed the robustness of the findings.
ResultsBlack had significantly lower PD-related mortality than White (adjusted mortality rate ratios [MRRs]: 0.62-0.69; all p<0.001), whereas AD-related mortality showed no significant racial differences (MRRs: 0.91-1.06). Compared with 2018, mortality increased significantly in 2020 for both diseases among White adults (AD: MRR=1.21; PD: MRR=1.27) and Black adults (AD: MRR=1.27; PD: MRR=1.37), followed by partial declines. PD-related mortality increased significantly among White adults during 2018-2023 (annual percentage change [APC]=3.08%; 95% CI: 1.15%-5.05%), whereas trends among Black adults (APC=3.51%; 95% CI: -2.94% to 10.39%) and AD-related mortality trends in both racial groups were not statistically significant. The disease-race-year interaction was not significant (p=0.942), indicating insufficient evidence that temporal mortality patterns differed jointly.
ConclusionsRecorded PD-related mortality was lower among Black than White adults, whereas AD-related mortality showed no statistically significant racial difference. These findings support disease-specific mortality surveillance and further investigation of potential differences in diagnostic recognition and death-certificate documentation.
Related
- National trends and disparities in coronary artery disease and depression-related mortality in the United States, 1999-2025: A population-based CDC WONDER analysis.
- Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims
- Racial, sex, and geographic disparities in mortality involving stroke and chronic kidney disease: a CDC WONDER database analysis, 1999–2020
- Trends and disparities in cerebrovascular disease mortality among patients with bronchus and lung cancer in the United States, 1999–2020: a population-based retrospective study
- Trends and disparities in depression-related mortality among older adults in the United States, 1999–2020
BibTeX
@misc{ahmmad2026racial,
title = {{Racial Disparities and Trends in Alzheimers and Parkinsons Disease-Related Mortality: A CDC WONDER Study 2018-2024}},
author = {M. R. Ahmmad},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.22.26366001},
url = {https://www.medrxiv.org/content/10.64898/2026.10.22.26366001v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Racial Disparities and Trends in Alzheimers and Parkinsons Disease-Related Mortality: A CDC WONDER Study 2018-2024
AU - M. R. Ahmmad
PY - 2026
DA - 2026/10/22
PB - medRxiv
DO - 10.64898/2026.10.22.26366001
UR - https://www.medrxiv.org/content/10.64898/2026.10.22.26366001v1
AB - ObjectiveThe objectives of this study were to examine racial differences and temporal trends in Alzheimers disease (AD)- and Parkinsons disease (PD)-related mortality among U.S. adults and to assess whether racial mortality patterns and temporal changes differed. MethodsWe analyzed CDC WONDER Multiple Cause of Death data from 2018-2024, where mortality was defined as deaths with AD or PD recorded as an underlying or contributing cause. Age-standardized mortality rates and adjusted mortality rate ratios (MRRs) were estimated. Joint-point regression evaluated racial differences, annual percentage changes (APCs), and disease-race-year interactions. Sensitivity analyses assessed the robustness of the findings. ResultsBlack had significantly lower PD-related mortality than White (adjusted mortality rate ratios [MRRs]: 0.62-0.69; all p<0.001), whereas AD-related mortality showed no significant racial differences (MRRs: 0.91-1.06). Compared with 2018, mortality increased significantly in 2020 for both diseases among White adults (AD: MRR=1.21; PD: MRR=1.27) and Black adults (AD: MRR=1.27; PD: MRR=1.37), followed by partial declines. PD-related mortality increased significantly among White adults during 2018-2023 (annual percentage change [APC]=3.08%; 95% CI: 1.15%-5.05%), whereas trends among Black adults (APC=3.51%; 95% CI: -2.94% to 10.39%) and AD-related mortality trends in both racial groups were not statistically significant. The disease-race-year interaction was not significant (p=0.942), indicating insufficient evidence that temporal mortality patterns differed jointly. ConclusionsRecorded PD-related mortality was lower among Black than White adults, whereas AD-related mortality showed no statistically significant racial difference. These findings support disease-specific mortality surveillance and further investigation of potential differences in diagnostic recognition and death-certificate documentation.
ER -